Merus (MRUS) Downgraded by BidaskClub

Share on StockTwits

Merus (NASDAQ:MRUS) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Thursday.

MRUS has been the topic of several other reports. Zacks Investment Research upgraded shares of Merus from a “hold” rating to a “buy” rating and set a $15.00 price objective on the stock in a research report on Friday, March 15th. ValuEngine upgraded shares of Merus from a “sell” rating to a “hold” rating in a research report on Wednesday, March 6th. Finally, Citigroup cut their price objective on shares of Merus from $18.00 to $16.00 and set a “neutral” rating on the stock in a research report on Friday, March 15th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $21.67.

Shares of NASDAQ:MRUS opened at $12.85 on Thursday. The stock has a market capitalization of $292.57 million, a P/E ratio of -3.00 and a beta of -0.12. Merus has a fifty-two week low of $11.00 and a fifty-two week high of $26.74.

Merus (NASDAQ:MRUS) last issued its quarterly earnings data on Thursday, December 27th. The biotechnology company reported ($0.55) earnings per share for the quarter. The firm had revenue of $7.57 million during the quarter, compared to the consensus estimate of $4.25 million. Merus had a negative net margin of 140.49% and a negative return on equity of 55.96%. On average, equities analysts predict that Merus will post -2.18 earnings per share for the current year.

A number of institutional investors have recently added to or reduced their stakes in MRUS. Artal Group S.A. acquired a new position in Merus during the 4th quarter valued at about $2,886,000. Laurion Capital Management LP acquired a new position in Merus during the 3rd quarter valued at about $2,104,000. Aquilo Capital Management LLC increased its stake in Merus by 3.6% during the 3rd quarter. Aquilo Capital Management LLC now owns 1,295,713 shares of the biotechnology company’s stock valued at $25,577,000 after buying an additional 44,799 shares during the period. Morgan Stanley increased its stake in Merus by 74.3% during the 3rd quarter. Morgan Stanley now owns 71,643 shares of the biotechnology company’s stock valued at $1,415,000 after buying an additional 30,538 shares during the period. Finally, JPMorgan Chase & Co. increased its stake in Merus by 33.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 17,723 shares of the biotechnology company’s stock valued at $350,000 after buying an additional 4,476 shares during the period. 53.06% of the stock is currently owned by hedge funds and other institutional investors.

Merus Company Profile

Merus NV is a clinical-stage immune-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg on June 16, 2003 and is headquartered in Utrecht, Netherlands.

See Also: Consumer behavior in bull markets

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Solarwindow Technologies  and Green Plains  Head to Head Comparison
Solarwindow Technologies and Green Plains Head to Head Comparison
StableUSD Reaches Market Capitalization of $5.90 Million
StableUSD Reaches Market Capitalization of $5.90 Million
Unikoin Gold  Hits 24-Hour Trading Volume of $13,765.00
Unikoin Gold Hits 24-Hour Trading Volume of $13,765.00
VapersCoin Price Hits $0.0000 on Major Exchanges
VapersCoin Price Hits $0.0000 on Major Exchanges
Financial Contrast: RLJ Lodging Trust  vs. Gecina
Financial Contrast: RLJ Lodging Trust vs. Gecina
$0.21 Earnings Per Share Expected for Garrison Capital Inc  This Quarter
$0.21 Earnings Per Share Expected for Garrison Capital Inc This Quarter


© 2006-2019 Ticker Report